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One sentence summary: 
An allele on chromosome 9 is systematically associated with a 20-40% increased risk of 
coronary heart disease. 
 
 1
Coronary heart disease (CHD) is a major cause of death in Western countries. Here we used 
genome-wide association scanning to identify a 58 kb interval on chromosome 9 that was 
consistently associated with CHD in six independent samples.  The interval contains no 
annotated genes and is not associated with established CHD risk factors such as plasma 
lipoproteins, hypertension or diabetes.  Homozygotes for the risk allele comprise 20-25% of 
Caucasians and have a ~30-40% increased risk of CHD.  These data indicate that the 
susceptibility allele acts through a novel mechanism to increase CHD risk in a large fraction 
of the population. 
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Coronary heart disease (CHD) is the single largest cause of death worldwide (1, 2).  
Numerous risk factors influence the development and severity of CHD, such as 
hypercholesterolemia, smoking, hypertension and diabetes (3).  Several of these risk factors 
have a major heritable component, but the nature of the DNA sequence variations that confer 
cardiovascular risk remain largely unknown.  Mutations responsible for Mendelian forms of 
hypercholesterolemia greatly increase the risk of coronary atherosclerosis, but these diseases 
account for only a small fraction of individuals with heart disease (4).  Single nucleotide 
polymorphism (SNP) association studies (3) and genome-wide linkage scans have reported 
common alleles associated with CHD risk (5-10), but none has been validated by replication 
in multiple cohorts. 
To identify sequence variants associated with CHD, we undertook a genome-wide 
association study using 100,000 SNPs.  To minimize false positive associations, without 
unduly sacrificing statistical power, we used an iterative case-control design comprising three 
sequential comparisons between cases and controls that were performed at a nominal 
significance threshold of P<0.025 (Figure 1).  Assuming independence, the probability of any 
single SNP achieving this level of significance in all three studies with the associations being 
in the same direction was 3.9 X 10-6 (0.0253 X 0.52).  Thus, none of the 100,000 SNPs would 
be expected by chance to replicate consistently in all three comparisons.  For the initial 
genome-wide scan, cases and controls were white men and women recruited from Ottawa, 
Canada to participate in the Ottawa Heart Study (OHS).  Cases had symptomatic CHD with 
documented onset before the age of 60 years and culminating in coronary artery 
revascularization (bypass grafting or percutaneous coronary intervention).  To limit 
confounding by known major risk factors that strongly predispose to premature CHD, 
individuals with diabetes, or with plasma cholesterol levels consistent with monogenic 
hypercholesterolemia (>280 mg/dL) were excluded.  Controls were healthy white men (>65 
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y) and women (>70 y) recruited at the same institution as the cases who had no symptoms or 
history of CHD. 
Custom oligonucleotide arrays (11) were used to assay 100,000 SNPs arranged at 
approximately 30 kb intervals throughout the genome in 322 cases and 312 controls (OHS-1).  
Of these, 9,636 SNPs deviated strongly from Hardy-Weinberg equilibrium (P<0.001) or did 
not meet quality-control criteria (11) and 17,500 were sub-polymorphic (minor allele 
frequency <1%) in the sample. The remaining 72,864 SNPs were entered into the analysis 
and 2,586 were associated with CHD in OHS-1 at a nominal significance threshold of 0.025 
(Table 1).  These 2,586 SNPs were genotyped in a second group of 311 cases and 326 
controls (OHS-2), selected from the same population using the same criteria as OHS-1.  Of 
these, 50 were associated with CHD at a nominal significance threshold of 0.025, with the 
same direction of effect. 
To limit attrition of true positive associations due to inadequate statistical power, the 
third case-control comparison was performed in the Atherosclerosis Risk in Communities 
(ARIC) study, a large prospective study of CHD risk that enrolled and followed 11,478 
European-Americans (12).  For this analysis, cases were defined as individuals with a 
documented CHD event (defined as myocardial infarction, coronary artery revascularization, 
or coronary death) during the 15 yr follow-up period of the study; individuals with prevalent 
disease at the baseline visit were excluded.  The study sample delineated by these criteria 
provides > 90% power to detect common alleles (minor allele frequency >0.1) that differ in 
frequency by 0.06 or more between cases and controls. Nonetheless, only two of the 50 SNPs 
identified in the Ottawa cohorts were significantly associated with incident CHD in the ARIC 
population (Table 1).  These two SNPs, rs10757274 and rs2383206, were located within 20 
kb of each other on chromosome 9 and were in strong linkage disequilibrium (r2=0.89). Both 
SNPs involve the substitution of G for A.  At both loci the A and G alleles were present at 
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almost equal frequencies among the controls in the three samples.  The presence of a G allele 
was associated with an increased risk of CHD in all three groups (OHS-1, OHS-2, and ARIC) 
(Table 2). 
To validate the association between rs10757274 and rs2383206 and CHD, both SNPs 
were assayed in three additional independent cohorts: the Copenhagen City Heart Study 
(CCHS), a prospective study of ischemic heart disease in 10,578 Danish men and women 
(13); the Dallas Heart Study (DHS), a population-based probability sample of Dallas County 
residents (14); and a third group of 647 cases and 847 controls from the Ottawa Heart Study 
population who had not been included in the genome-wide scan or in the first replicate 
analysis (OHS-3).  In the CCHS, cases were individuals who experienced an ischemic 
cardiovascular event during the 20 yr follow-up period while controls were those who did not 
develop incident disease.  In the DHS, electron-beam computer tomography was used to 
measure coronary artery calcium (CAC), an index of coronary atherosclerosis (15).  Each 
individual underwent two consecutive scans.  The distribution of CAC scores is extremely 
skewed and inter-scan variability is high for scores below 10 Agatston units (16), therefore 
we excluded individuals with CAC scores between 2 and 10 units and divided the population 
into controls (CAC scores of ≤ 2 units, n=575) and cases (those with CAC scores ≥10 units, 
n=166), as previously described (16).  In OHS-3, cases had documented CHD before the age 
of 55 (men) or 65 (women), whereas controls were men and women aged > 70 years who did 
not have symptoms of CHD. In all three validation studies, both SNPs were significantly 
associated with CHD (Table 2).  These data further support the association between the G 
alleles of rs10757274 and rs2383206 and CHD. 
The magnitude of incident CHD associated with the G allele was determined by Cox 
proportional-hazards modeling in the ARIC and CCHS cohorts. The hazard ratios associated 
with the risk alleles were comparable in the two populations, and indicated a graded increase 
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in risk from noncarriers to heterozygotes to homozygotes (Table 3).  The two SNPs 
(rs10757274 and rs2383206) define an allele that is associated with a ~15-20% increase in 
risk in the 50% of individuals who are heterozygous for the allele and ~30-40 % increase in 
CHD in the 25% of individuals of European descent who are homozygotes.  The population 
attributable risk associated with the risk allele was 12.5-15% in the ARIC population and 10-
13% in the CCHS cohort. 
The mechanistic basis for the association of the allele defined by rs10757274 and 
rs2383206 and CHD is not known.  The risk allele may promote CHD by increasing the 
development of atherosclerotic plaques in the coronary arteries, by promoting 
thrombogenesis, or by increasing the tendency of atherosclerotic plaques to rupture.  The 
finding that the risk allele was associated with increased coronary artery calcification in the 
DHS suggests that it promotes CHD by increasing the atherosclerotic burden.  This notion is 
supported by the observation that the prevalence of the risk allele was greatest among cases 
in OHS-1, who were ascertained for severe premature atherosclerosis rather than for cardiac 
events.  To determine if the atherogenic effects of the risk allele are mediated via established 
risk factors for coronary artery atherosclerosis, we tested for association between the risk 
allele and intermediate phenotypes in the ARIC and CCHS populations.  In both cohorts, the 
risk allele was not significantly associated with systolic or diastolic blood pressure, fasting 
blood glucose or diabetes, or plasma levels of lipids or lipoprotein-cholesterol 
(Supplementary Tables 1 and 2).  The risk allele was associated with a slight but statistically 
significant decrease in body mass index in the ARIC cohort, but not in the CCHS population.  
Thus, the effect of the chromosome 9 risk allele on CHD is not mediated by any of the 
established major risk factors for the disease. 
To fine-map the interval associated with CHD, SNPs spaced  at ~5 kb intervals across 
the region extending 175 kb upstream and downstream of rs10757274 and rs2383206 were 
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assayed in 500 cases and 500 controls from OHS-1 and OHS-2.  Eight additional SNPs at the 
locus spanning a 58 kb region (extending from 22,062,301 to 22,120,389) were significantly 
associated with CHD (Figure 2).  All eight were in strong linkage disequilibrium with each 
other and with rs10757274 and rs2383206.  The region demarcated by these SNPs was 
flanked on both sides by ~50 kb regions in which none of the 30 SNPs tested were associated 
with CHD, even at a nominal significance threshold of 0.025.  Two of 65 SNPs in the 350 kb 
region surrounding the 58 kb risk locus were associated with CHD at the nominal 
significance threshold, but neither of these SNPs was in linkage disequilibrium with 
rs10757274 and rs2383206.  These data indicate that the risk allele comprises a single 
haplotype that spans ~58 kb. 
Inspection of the UCSC Genome Browser and BLAST searches against the NCBI nr 
nucleotide sequence database revealed no annotated genes or microRNAs within the 58 kb 
interval.  Thus, the nucleotide changes associated with the risk allele do not alter the coding 
sequence of a known gene.  A number of spliced ESTs map within the interval, but none 
contain open reading frames that extend more than a few amino acids.  As a first step towards 
identifying functional elements responsible for the observed association, we sequenced the 58 
kb interval in two homozygotes for the risk allele, and in one individual who was 
homozygous for the reference allele.  Of the 66 polymorphisms (SNPs plus small insertions 
or deletions) identified in the 6 alleles that were sequenced, 35 were specific to the risk allele 
(Supplementary Table 3).  Only one of these variants, a copy number variation in a run of 9 
consecutive CAT repeats (extending from nucleotide 22110787 to 22110814, NCBI build 
36.1) mapped to a spliced transcript (BI765545) that appears to be part of a large noncoding 
RNA, DQ485453 (17).  PCR amplification of cDNAs confirmed expression of the transcript 
in placenta and transformed lymphocytes (data not shown).  Whereas the function of 
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DQ485453 is not known, it is possible that variation in the expression or function of this 
transcript may be associated with risk of CHD. 
Alternatively the risk allele may alter the sequence of a regulatory element that affects 
the expression of a gene(s) located outside of the 58 kb interval.  Cross-species sequence 
alignments using VISTA revealed several segments within the 58 kb interval that are 
conserved among humans, dogs and mice that may contain such regulatory elements 
(Supplementary Figure 1).  It is also possible that the risk allele extends beyond the 58 kb 
interval defined in this study, and that the functional sequence variants that confer risk of 
CHD are located outside of the interval.  Resequencing the coding regions of the two genes 
most proximal to the risk locus, CDKN2A and CDKN2B, which lie 70-100 kb telomeric to 
the interval (Figure 2), revealed only a single variant (A158S in CDKN2A) that was present 
in 6 of the 96 apparently healthy white men and women examined.  The localization of the 
risk locus to a region devoid of known genes implicates a previously unrecognized gene that 
can substantially affect CHD risk independently of the established CHD risk factors.  Further 
studies will be required to elucidate the mechanism by which allelic variation at the locus 
modulates risk of coronary heart disease. 
The greater haplotype diversity found in populations of African descent (18) may be 
useful for fine localization of functional sequence variants responsible for genetic 
associations.  Comparison of the Yoruba and CEPH data from the HapMap revealed striking 
ethnic differences in the frequencies of alleles in the risk interval (Supplementary Table 4).  
Of the 10 alleles that were significantly associated with CHD in whites, 3 were virtually 
absent from the Yoruba population, and 6 others significantly less common.  Both 
rs10757274 and rs2383206 were present at appreciable frequencies among African-
Americans in ARIC and DHS, but neither SNP was associated with CHD in either population 
(Supplementary Table 5).  It is possible that the apparent ethnic differences in association 
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between these SNPs and CHD in ARIC are a spurious consequence of differences statistical 
power: there are significantly fewer African-Americans than whites in the ARIC study.  
However inadequate statistical power cannot explain the ethnic differences observed in DHS, 
since African-Americans are the largest group in this study.  Accordingly, it seems more 
likely that the functional sequence variants associated with the risk allele in whites are less 
common in African-Americans.  This notion is consistent with our finding that the 
frequencies of several alleles associated with CHD risk factors differ widely between these 
ethnic groups (19-21).  Comprehensive analysis of the locus in African-Africans may allow 
further refinement of the risk interval. 
The results of this study illustrate both the perils and the promise of whole-genome 
association.  The initial scan and the first replicate screen both generated substantially more 
SNPs that achieved the pre-specified significance threshold than would be predicted by 
chance alone, as indicated by permutation testing.  Yet only two of these SNPs (comprising 
one allele) survived further replication, despite the use of a large sample (i.e. ARIC) with 
high statistical power.  This finding highlights the necessity for adequate replication to 
protect against artifacts that may occur due to population stratification, multiple testing, or 
other factors to which whole-genome association studies are particularly susceptible.  The 
consistent replication of the chromosome 9 risk allele in six independent study samples 
indicates that the approach can be productively applied to conditions as complex as CHD, 
which is known to be influenced by a variety of environmental and genetic factors (22).  
Analysis of 50 randomly selected regions of 500 kb each indicated that the 72,864 
informative SNPs used in the initial scan provided 30-40% of the power that would be 
obtained by assaying all Phase II Hapmap SNPs. Therefore scans with denser SNP panels 
may reveal further loci associated with CHD risk. 
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Table 1. SNP associations in a genome-wide association scan in OHS-1 and replication 
studies in OHS-2 and ARIC. 
Values in the table are numbers of SNPs.  P-values for the number of SNPs observed relative 
to the number expected were derived empirically from 1000 permutations in which case-
control status was randomized.  SNPs in the ARIC cohort were tested for association with 
incident CHD.  Individuals with prevalent CHD at baseline were excluded. 
OHS, Ottawa Heart Study; ARIC, Atherosclerosis Risk in Communities Study; SNP, single 
nucleotide polymorphism 
 
Cohort SNPs Assayed 
SNPs with P<0.025 
Observed 
SNPs with P<0.025 
Expected 
Observed-
Expected P 
OHS-1 72,864 2,586 2,066 520 <0.001
OHS-2 2,083 50 26 24 <0.001
ARIC 50 2 0 2 NA 
.
Table 2. Association between SNPs rs10757274 and rs2383206 and CHD. 
Values are numbers of individuals in each genotype group.  P-values were calculated by Chi-Square tests on allele counts.  
OHS, Ottawa Heart Study, ARIC, Atherosclerosis Risk in Communities Study; CCHS, Copenhagen City Heart Study, DHS, Dallas Heart Study, 
SNP, single nucleotide polymorphism. 
 
 rs10757274 rs2383206 
Cohort Controls Cases  Controls Cases  
 AA AG GG AA AG GG P AA AG GG AA AG GG P 
OHS-1 85 149 78 49 148 125 4.8X10-6 77 147 88 45 140 137 8.1X10-6 
OHS-2 85 161 80 56 140 108 0.002 80 160 86 50 141 113 0.001 
ARIC 2063 3822 1858 230 525 282 0.001 2140 4161 2231 230 600 324 0.001 
CCHS 2752 4543 1758 393 792 340 0.0001 2489 4583 1981 372 782 371 0.005 
DHS 161 283 131 28 92 46 0.025 144 284 147 25 91 50 0.023 
OHS-3 228 418 201 121 333 193 0.0001 197 416 229 115 327 209 0.004 
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Atherosclerosis Risk in Communities Study Copenhagen City Heart Study 
Number of Events   Number of Events    
n (%) Observed Expected1 Incidence2 Hazard Ratio n (%) Observed Expected Incidence Hazard Ratio 
rs10757274        
AA 2,293 (26) 2553 295 79 (70-89) 1 3,145 (30) 3935 473 61(55-68) 1 
AG 4,347 (50) 564 553 93 (86-101) 1.18 (1.02-1.37) 5,335 (50) 792 755 73 (68-79) 1.26 (1.12-1.42) 
GG 2,140 (24) 298 269 101 (90-114) 1.29 (1.09-1.52) 2,098 (20) 340 296 80 (72-89) 1.38 (1.19-1.60) 
rs2383206        
AA 2,370 (25) 2594 310 78 (69-88) 1 2,861 (27) 3726 425 64 (58-71) 1 
AG 4,761 (49) 643 610 97 (90-105) 1.26 (1.09-1.46) 5,365 (51) 782 772 72 (67-77) 1.16 (1.02-1.31) 
GG 2,555 (26) 345 327 97 (88-108) 1.26 (1.07-1.48) 2,352 (22) 371 327 78 (71-87) 1.29 (1.12-1.50) 
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Table 3. Risk of CHD as a function of rs10757274 and rs2383206 in the Atherosclerosis Risk in Communities Study and the Copenhagen City 
Heart Study.  
1Based on the Log-rank test.  2Incidence rate measured in number of events per 10,000 person years of follow-up.  3p<0.0111 
4p<0.0041.  5p<0.00001. 6p<0.005
 
 
Figure Legends 
Figure 1. Study design for identification and validation of sequence variants associated with 
coronary heart disease. 
Figure 2. Fine mapping of the genomic interval on chromosome 9 associated with coronary 
heart disease.  SNPs spaced ~5 kb apart in the interval extending 175 kb upstream and 
downstream of rs10757274 and rs2383206 were assayed in 500 cases and 500 controls from 
the Ottawa Heart Study population. Bars represent P values (determined using Chi-Square 
tests) for differences in allele frequency between cases and controls.  Arrowheads indicate 
rs10757274 and rs2383206. The shaded box represents the risk interval.  The linkage disequilibrium
map indicates pairwise r2 values.  Blocks are shaded on a continuous scale where white represents
 an r2 of 0 and black represents an r2 of 1. 
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Materials and Methods: 
 
Study Populations 
 
1) The Ottawa Heart Study.  White men and women with premature CAD defined as > 50% 
stenosis in > 1 coronary artery and age of onset < 55y (M) and <65 y (F) were recruited from 
the patient population of the University of Ottawa Heart Institute in Ottawa, Canada..  
Individuals with advanced disease requiring coronary artery bypass grafting or percutaneous 
coronary intervention who did not have a history of diabetes mellitus or severe dyslipidemia, 
suggestive of a monogenic lipid disorder (TC>280 mg/dl/7.0 mmol/L) were included in the 
initial genome-wide scan (OHS1) and in the first replication (OHS 2).  The mean age of onset 
of CAD in these individuals was 47.8+7.5(SD) years.  Healthy elderly men (> 65 y) and 
women (> 70y) of the same ethnic background as the CAD cases were recruited from the 
Ottawa region.  Clinical history and systems review revealed no indicators of clinical CAD.  
The mean age of the control subjects was 74.9+4.8(SD) years. 
2) The Atherosclerosis Risk in Communities Study (ARIC).  The ARIC study comprised men 
and women aged 45 to 64 years who were randomly selected from four communities 
(Jackson, MS; Minneapolis MN; Forsyth County, NC; and Washington County, MD).  Race 
or ethnic group was determined by self-identification; participants described themselves as 
black or white in response to a questionnaire on which the available categories were "black", 
"white", "Indian", or "Asian". Plasma lipids, glucose, insulin and lipoproteins were assayed in 
the ARIC central lipid laboratory with commercial reagents, as previously described 1-3. 
3) The Copenhagen City Heart Study (CCHS). The Copenhagen City Heart Study population 
was randomly drawn from the Copenhagen Population Register in January 19764. The sample 
was drawn from a population of approximately 90 000 inhabitants 20 years and older living 
within 10 wards surrounding Rigshospitalet, the National University Hospital of Copenhagen. 
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A second examination was performed 5 years later (1981-1983), and a third examination was 
performed after 15 years (1991-1994), at which time blood samples were obtained from 
9,259 individuals for isolation of DNA. A self-administered questionnaire was used to obtain 
information regarding familial history, education and socio-economic status, and smoking 
and drinking habits. Plasma cholesterol and triglyceride levels were determined 
enzymatically using commercial reagents, and HDL-C was determined after removal of 
apoB-containing lipoproteins by precipitation with phosphotungstic acid and magnesium. 
Participants were white and of Danish descent. 
4) The Dallas Heart Study. The Dallas Heart Study is a multi-ethnic, population-based 
probability sample of Dallas County residents.  The study included three phases: an in-home 
interview, an in-home phlebotomy visit, and a clinic visit during which a variety of imaging 
examinations were performed.  White men and women who underwent electron-beam 
computer tomography to assess coronary artery calcification were eligible for the present 
study.  
Genotyping:  
1) Oligonucleotide hybridization.  A total of 100,000 sequence variants spavced at * kb 
intervals across the genome were assayed by hybridization to oligonucleotides arrays 
synthesized on glass slides as described5.  Briefly, each SNP was interrogated by 24 25mer 
oligonucleotide probes targeting both the reference and alternate alleles on forward and 
reverse strands. Each allele and strand was represented by six oligonucleotides comprising 
five perfect match probes and one mismatch.  
2) Mass Spectrometry.  The 50 sequence variants identified in the genome-wide scan were 
assayed in the ARIC population by mass spectrometry using the Sequenom MassARRAY 
system (Sequenom, Inc.; San Diego, CA).  
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3) Fluorogenic 5'-nucleotidase assays for rs10757274 and rs2383206 were developed with the 
use of the TaqMan assay system (Applied Biosystems). The assays were performed on a 
7900HT Fast Real-Time PCR instrument with probes and reagents purchased from Applied 
Biosystems.  
DNA sequencing.  The 58 kb interval between rs12555547 and rs10965244 was sequenced 
in two individuals homozygous for the risk allele, and in one individual homozygous for the 
wild-type allele as described6.  The coding region and flanking intronic sequences of 
CDKN2A and CDKN2B were sequenced in 96 healthy white men.  All sequence variants 
identified were verified by manual inspection of the chromatograms and missense changes 
were confirmed by an independent resequencing reaction. 
Reverse transcription and PCR Amplification of cDNAs.  RNA was isolated from human 
brain, liver, placenta, and lymphocytes by a modified phenol-chloroform extraction (TRIZOL 
reagent, Invitrogen Corporation, Carlsbad, CA), and reverse transcribed (SuperScript III 
First-strand synthesis system, Invitrogen).  Aliquots of cDNA were amplified using primers 
directed against spliced ESTs CN277071, BX100299 and DQ485453.  Primer sequences are 
available from the authors upon request. 
Statistical Analysis. For the genome-wide scan, allelic associations were evaluated for each 
SNP using chi-square tests on 2×2 contingency tables with no adjustments.  Calculations 
were performed independently at Perlegen Sciences and at UT Southwestern and essentially 
identical results were obtained. To determine the empirical P-values we randomized the 
sample case/control status 1,000 times, and calculated allelic associations on each permuted 
dataset. SNPs that were significantly associated with CHD in the genome-wide scan were 
assayed in a second set of cases and controls and analyzed using Chi-square tests and 
permutation testing.  For the remaining data sets, case-control differences in allele 
frequencies of rs10757274 and rs2383206 were evaluated using chi-square tests on 3X2 
 3
contingency tables.  Population attributable risk was calculated using the formula PAR = I(T) 
– I(0), where I(T) is the total disease incidence in the population, and I(0) is the disease 
incidence in unexposed individuals. 
References: 
1. Investigators, T.A.S. The Atherosclerosis Risk in Communities (ARIC) Study: 
design and objectives. The ARIC investigators. Am J Epidemiol 129, 687-702 
(1989). 
2. Chambless, L.E. et al. Coronary heart disease risk prediction in the 
Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol 56, 880-
90 (2003). 
3. Brown, S.A. et al. Plasma lipid, lipoprotein cholesterol, and apoprotein 
distributions in selected U.S. communities. Arteriscler. Thromb 13, 1139-1158 
(1993). 
4. Schnohr, P., Jensen, G., Scharling, H. & Appleyard, M. The Copenhagen City 
Heart Study. Osterbroundersogelsen.  Tables with data from the third 
examination 1991-94. European Heart Journal 3, Suppl H., H1-H83 (2001). 
5. Saccone, S.F. et al. Cholinergic nicotinic receptor genes implicated in a 
nicotine dependence association study targeting 348 candidate genes with 
3713 SNPs. Hum Mol Genet 16, 36-49 (2007). 
6. Tartaglia, M. et al. Gain-of-function SOS1 mutations cause a distinctive form 
of Noonan syndrome. Nat Genet 39, 75-9 (2007). 
7. Yang, J. et al. Decreased lipid synthesis in livers of mice with disrupted Site-1 
protease gene. Proc Natl Acad Sci U S A 98, 13607-13612 (2001). 
 
 
 4
MOUSE
DOG
OPPOSUM
rs10757274 rs2383206
DQ485453
22,062K 22,072K 22,082K 22,092K 22,102K 22,112K 22,121K
100%
750%
50%
50%
HUMAN vs.
750%
750%
5’ 3’
Supplementary Figure 1. Evolutionary conservation in the risk interval on Chromosome 9.   
Supplementary Table 1. Clinical and laboratory characteristics of participants in the ARIC Study. 
 rs10757274 rs2383206 
 AA AG GG P-value AA AG GG P-value 
N 2,293 4,347 2,140 - 2,370 4,761 2,555 - 
M/F 1,057/1,236 1,972/2,375 958/1,182 0.67 1,106/1,264 2,160/2,601 1,152/1,403 0.48 
Age (years) 54±6 54±6 54±6 0.76 54±6 54±6 54±6 0.09 
BMI (kg/m2) 27.2±5.0 26.9±4.8 26.8±4.7 0.004 27.2±5.0 26.9±4.8 26.9±4.8 0.01 
SBP (mm/Hg) 119±17 118±17 118±17 0.44 119±17 118±17 118±17 0.53 
DBP (mm/Hg) 72±10 72±10 71±10 0.28 72±10 71±10 72±10 0.06 
Glucose (mg/dL) 106±33 105±32 104±25 0.07 105±30 105±32 104±26 0.29 
Cholesterol (mg/dL) 215±39 215±41 213±40 0.16 214±39 215±41 213±40 0.17 
Triglyceride (mg/dL) 116 (82-167) 112 (80-160) 112 (80-162) 0.16 115 (82-166) 112 (81-160) 113 (81-162) 0.28 
LDL-C (mg/dL) 137±37 137±38 135±37 0.23 137±37 137±39 136±37 0.27 
HDL-C (mg/dL) 51±17 51±17 51±16 0.56 51±17 51±17 51±16 0.16 
Values are means ± standard deviations, except for triglycerides which are medians (interquartile ranges). P-values were calculated using  
ANOVA. Variables with highly skewed distributions (triglycerides) were log transformed prior to analysis. 
 
Supplementary Table 2. Clinical and laboratory characteristics of participants in the Copenhagen City Heart Study. 
 rs10757274 rs2383206 
 AA AG GG P-value AA AG GG P-value 
N 3,145 5,335 2,098 - 2,861 5,365 2,352 - 
M/F 1,358/1,787 2,401/2,934 952/1146 0.18 1,233/1,628 2,395/2,970 1,083/1,269 0.10 
Age (years) 58±15 57±15 57±15 0.29 58±12 58±15 57±15 0.10 
BMI (kg/m2) 26±4 26±4 26±4 0.57 25±4 26±4 26±4 0.24 
SBP (mm/Hg) 139±23 138±22 139±23 0.59 139±23 139±22 139±23 0.96 
DBP (mm/Hg) 84±12 84±12 84±12 0.38 84±12 84±12 84±12 0.22 
Glucose (mg/dL) 104±34 105±36 105±34 0.35 105±35 105±35 105±34 0.60 
Cholesterol (mg/dL) 237±50 238±49 236±52 0.40 237±50 238±49 236±52 0.29 
Triglyceride (mg/dL) 135 (96-202) 133 (96-196) 137(96-194) 0.98 135 (96-202) 136(96-196) 137 (96-194) 0.88 
LDL-C (mg/dL) 161±48 162±47 161±47 0.43 161±48 162±47 161±47 0.40 
HDL-C (mg/dL) 61±19 61±19 60±19 0.64 61±19 61±19 60±19 0.41 
Values are means ± standard deviations, except for triglycerides which are medians (interquartile ranges). P-values were calculated using  
ANOVA. Variables with highly skewed distributions (triglycerides) were log transformed prior to analysis. 
 
Supplementary Table 3.  Sequence variations identified in the 58 kd risk interval on  
chromosome 9 in two individuals homozygous for the risk allele and one homozygo
for the alternate allele.
Position Type Allele Risk Genotype Referent Genotype
Major Minor 1 2 1
22062264 SNP A G G/G G/G A/A
22062301 SNP G C C/C C/C G/G
22062638 SNP G A A/A A/A G/G
22062719 SNP A G G/G G/G A/A
22063996 SNP T G G/G G/G N/N
22067543 SNP C T T/T T/T N/N
22071397 SNP G T T/T T/T G/G
22071850 SNP C T T/T T/T C/C
22072375 SNP A C A/C A/A A/A
22073209 SNP C T C/C C/T N/N
22073400 SNP A T A/T A/A N/N
22073404 SNP C T T/T T/T N/N
22074310 SNP C T T/T T/T N/N
22075598 SNP T C C/C C/C N/N
22077473 SNP T C C/C C/C C/T
22078090 SNP A T T/T T/T A/A
22078094 SNP A G G/G G/G A/A
22078260 SNP C T T/T T/T C/C
22078465 DEL CA -- -/- -/- CA/CA
22089568 SNP C A A/A A/A N/N
22089755 INS - A A/A A/A -/-
22090176 SNP G C C/C C/C G/G
22091702 SNP T C C/C C/C T/T
22092165 SNP C T T/T T/T C/C
22092437 SNP G A G/G G/G A/G
22093183 SNP G T T/T T/T G/G
22093341 SNP T G G/G G/G T/T
22093813 SNP A G G/G G/G A/A
22095927 SNP T C C/C C/C T/T
22096225 SNP G A A/A A/A N/N
22096271 SNP A G G/G G/G N/N
22096400 SNP G A A/G G/G N/N
22096731 SNP T A A/A A/A T/T
22097238 SNP A T A/A A/A A/T
22100131 SNP T C C/C C/C T/T
22101587 INS ----- TTGAT TTGAT/ TTGAT/ -/-
TTGAT TTGAT
22102241 SNP A C C/C C/C A/A
22102427 SNP A G G/G G/G A/A
22102599 SNP T C C/C C/C N/N
22104469 SNP G C C/C C/C G/G
22104495 SNP A G G/G G/G A/A
22105026 SNP A G G/G G/G A/A
22105286 SNP T C C/C C/C T/T
22105589 SNP A T T/T T/T N/N
22105959 SNP A G G/G G/G A/G
22106046 SNP A G G/G G/G A/A
22106071 SNP T C C/C C/C C/T
22106220 SNP T C C/C C/C T/T
22107781 SNP C T C/T C/C C/C
22110491 INS - T T/T T/T -/-
22110813 DEL CAT --- -/- -/- CAT/-
22113766 SNP A C C/C C/C A/A
22114123 SNP T A A/A A/A T/T
22114140 SNP A T T/T T/T A/A
22115347 SNP A C C/C C/C A/A
22115503 SNP G C C/C C/C G/G
22115913 SNP C T T/T T/T N/N
22117613 SNP C T C/T C/C C/C
22117641 SNP G A A/G G/G G/G
22117879 SNP A G A/G A/G A/A
22118166 INS -- AT AT/- AT/- -/-
22118600 SNP G A A/G A/G N/N
22118730 SNP C G C/G C/C N/N
22119594 SNP G C C/C C/C C/C
22119724 INS - T T/T T/- T/T
22120389 SNP A T A/T A/T A/A
Supplementary Table 4.  Allele frequencies of chromosome 9 sequence 
variants associated with Coronary Heart Disease in whites. 
 
  Minor Allele Frequency 
SNP ID Position Whites African-Americans 
    
rs9632884 22062301 0.48 0.008 
rs6475606 22071850 0.5 0.008 
rs10757272 22078260 0.5 0.15 
rs10757274 22086055 0.49 0.21 
rs4977574 22088574 0.5 0.08 
rs2891168 22088619 0.5 0.08 
rs1333042 22093813 0.49 0.008 
rs2383206 22105026 0.49 0.41 
rs1333048 22115347 0.49 0.25 
rs1333049 22115503 0.49 0.175 
 
 
 
Supplementary Table 5.  Association between rs10757274 and 2383206 and CHD in African-Americans. 
 
 
 rs10757274 rs2383206 
Cohort Controls Cases  Controls Cases  
 AA AG GG AA AG GG P AA AG GG AA AG GG P 
ARIC 1857 971 143 187 92 14 0.90 1019 1532 541 114 161 46 0.32 
DHS 447 251 32 175 66 21 0.64 231 371 129 90 123 48 0.67 
Values in the table are numbers of individuals.  P values were calculated using Chi-square tests.   
